Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Giergiczny M, Dekker T, Hess S, Chintakayala P. Testing the stability of utility parameters in repeated best, repeated best-worst and one-off best-worst studies. Eur J Trans Infra. 2017 Sep 1;17(4):457-76. doi: 10.18757/ejtir.2017.17.4.3209
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Ibañez A, Aguado J, Baez S, Huepe D, Lopez V, Ortega R, Sigman M, Mikulan E, Lischinsky L, Torrente F, Cetkovich M, Torralva T, Bekinschtein T, Manes F. From neural signatures of emotional modulation to social cognition: individual differences in healthy volunteers and psychiatric participants. Soc Cogn Affect Neur. 2014 Jul;9(7):939-50.